The microenvironment of DLBCL is characterized by noncanonical macrophages recruited by tumor-derived CCL5.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
09 11 2021
09 11 2021
Historique:
received:
05
01
2021
accepted:
17
06
2021
pubmed:
14
9
2021
medline:
30
11
2021
entrez:
13
9
2021
Statut:
ppublish
Résumé
Tissue invasion by tumor cells induces a host inflammatory response that variably impacts tumorigenesis. This has been well documented for tumor-associated macrophages (TAMs) that could play a pro/M2- or an anti/M1-tumoral function. TAMs frequently infiltrate diffuse large B-cell lymphoma (DLBCL), an aggressive neoplasm arising from germinal center-experienced B cells. However, the pathway leading to the presence of TAMs in DLBCL remains unknown, and their impact is unclear. Here, we show that some DLBCL tumor cells expressed the chemokine CCL5, enabling the differential recruitment of blood monocytes through their expression of CCR1 and CCR5. CCL5 expression by DLBCL was not related to molecular subtypes, and healthy tonsillar B cells did not produce this chemokine, implying a posttransformation event. A single-cell analysis revealed that most DLBCL TAMs had a noncanonical gene signature with the concomitant expression of M1 and M2 genes. The presence of noncanonical TAMs may explain the lack of impact of macrophages on DLBCL development reported in some survival studies.
Identifiants
pubmed: 34516642
pii: S2473-9529(21)00544-9
doi: 10.1182/bloodadvances.2021004203
pmc: PMC8579261
doi:
Substances chimiques
CCL5 protein, human
0
Chemokine CCL5
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4338-4351Informations de copyright
© 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Références
Mol Med Rep. 2014 Sep;10(3):1231-6
pubmed: 24938715
Nature. 2000 Feb 3;403(6769):503-11
pubmed: 10676951
Blood. 2014 Feb 20;123(8):1214-7
pubmed: 24398326
Cancer Res. 2017 Mar 1;77(5):1097-1107
pubmed: 27923834
Cancer Res. 2006 Jan 15;66(2):605-12
pubmed: 16423985
Blood. 2009 Dec 10;114(25):5173-81
pubmed: 19846886
BMC Cancer. 2019 Nov 6;19(1):1049
pubmed: 31694577
Mol Med Rep. 2011 Sep-Oct;4(5):837-41
pubmed: 21701779
Ann Oncol. 2018 Dec 1;29(12):2363-2370
pubmed: 30307529
Genome Biol. 2017 Dec 20;18(1):234
pubmed: 29262845
Nat Med. 2018 May;24(5):679-690
pubmed: 29713087
Haematologica. 2015 Feb;100(2):143-5
pubmed: 25638802
Int J Cancer. 2003 Nov 1;107(2):197-201
pubmed: 12949794
Front Immunol. 2017 Jul 14;8:828
pubmed: 28769933
Mediators Inflamm. 2014;2014:292376
pubmed: 24523569
Int J Mol Sci. 2018 Jun 19;19(6):
pubmed: 29921749
Eur J Immunol. 1992 Jun;22(6):1477-81
pubmed: 1376260
Biochim Biophys Acta. 2016 Jan;1865(1):23-34
pubmed: 26145884
N Engl J Med. 2018 Apr 12;378(15):1396-1407
pubmed: 29641966
F1000Prime Rep. 2014 Mar 03;6:13
pubmed: 24669294
Cell. 2018 Aug 23;174(5):1293-1308.e36
pubmed: 29961579
Front Immunol. 2014 Oct 10;5:500
pubmed: 25346736
Nat Rev Drug Discov. 2018 Dec;17(12):887-904
pubmed: 30361552
Nat Med. 2015 Aug;21(8):938-945
pubmed: 26193342
Nat Rev Immunol. 2015 Mar;15(3):172-84
pubmed: 25712152
Blood Cancer J. 2021 Jan 7;11(1):2
pubmed: 33414466
PLoS Comput Biol. 2015 Jan 29;11(1):e1004077
pubmed: 25633866
Immunity. 2017 Aug 15;47(2):323-338.e6
pubmed: 28813661
Haematologica. 2019 Mar;104(3):564-575
pubmed: 30309853
Annu Rev Physiol. 2017 Feb 10;79:541-566
pubmed: 27813830
Br J Haematol. 2012 Nov;159(4):441-53
pubmed: 22970711
J Pathol. 2010 Jul;221(3):248-63
pubmed: 20527019
N Engl J Med. 2008 Nov 27;359(22):2313-23
pubmed: 19038878
Blood. 2010 Nov 18;116(20):e81-9
pubmed: 20610814
Mol Cancer Ther. 2005 Dec;4(12):1867-79
pubmed: 16373702
Int J Cancer. 2008 Feb 15;122(4):769-76
pubmed: 17935139
J Leukoc Biol. 2007 Sep;82(3):567-75
pubmed: 17575267
Cell Rep. 2016 Nov 22;17(9):2445-2459
pubmed: 27840052
Cancer Sci. 2011 Jun;102(6):1236-41
pubmed: 21392167
Nat Rev Cancer. 2014 Aug;14(8):517-34
pubmed: 25008267
Molecules. 2018 Dec 20;24(1):
pubmed: 30577495
Am J Blood Res. 2020 Aug 25;10(4):97-108
pubmed: 32923089